|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1991-3-15
|
|
pubmed:abstractText |
Spironolactone partially inhibited the specific binding of (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil to vascular smooth muscle membranes. It is suggested that spironolactone interacts at a binding site of the calcium channel complex and allosterically modulates ligand binding at receptor sites in the channel.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2149292-Animals,
pubmed-meshheading:2149292-Binding Sites,
pubmed-meshheading:2149292-Calcium Channel Blockers,
pubmed-meshheading:2149292-Cell Membrane,
pubmed-meshheading:2149292-Horses,
pubmed-meshheading:2149292-Isradipine,
pubmed-meshheading:2149292-Ligands,
pubmed-meshheading:2149292-Muscle, Smooth, Vascular,
pubmed-meshheading:2149292-Portal Vein,
pubmed-meshheading:2149292-Progesterone,
pubmed-meshheading:2149292-Pyridines,
pubmed-meshheading:2149292-Spironolactone,
pubmed-meshheading:2149292-Verapamil
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Interactions of spironolactone with (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil binding sites in vascular smooth muscle.
|
|
pubmed:affiliation |
Laboratoire de Physiologie Cellulaire et Pharmacologie Moléculaire, INSERM Jeune Formation 88-13, Université de Bordeaux, France.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
